Log In
BCIQ
Print this Print this
 

biosimilar trastuzumab (ABP 980)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar of trastuzumab, a humanized mAb against EGFR2
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive breast cancer
Regulatory Designation
PartnerAllergan plc;
Daiichi Sankyo Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today